Hot Features
プレミアム
Thermfischer DRN (TMOS34)
BOV
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Mr. Dion J. WeislerIndependent Director | -80.29 | 36.27k | Sale to Issuer | 451.79 | 4.95k | -1.60% |
| 2026-04-27 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400.00 | 185.06k | Automatic Disposition | 462.66 | 25.05k | -1.57% |
| 2026-03-11 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -1.61k | 802.54k | Automatic Disposition | 499.40 | 18.32k | -8.06% |
| 2026-03-05 | Mr. Marc N. CasperChairman & CEO | -4.00k | 820.74k | Derivative Exercise and Sale | 309.63 - 519.74 | 141.91k | - |
| 2026-03-03 | Mr. Marc N. CasperChairman & CEO | -10.00k | 1.98M | Derivative Exercise and Sale | 309.63 - 516.75 | 141.91k | - |
| 2026-02-28 | Mr. Marc N. CasperChairman & CEO | -4.68k | 2.44M | Sale to Issuer | 521.11 | 141.91k | -3.20% |
| 2026-02-28 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -348.08 | 181.39k | Sale to Issuer | 521.11 | 13.33k | -2.54% |
| 2026-02-28 | Mr. Joseph R. HolmesVP & CAO | -116.63 | 60.77k | Sale to Issuer | 521.11 | 2.52k | -4.42% |
| 2026-02-28 | Mr. Michel Lagardeインサイダー | -1.20k | 623.56k | Sale to Issuer | 521.11 | 85.15k | -1.39% |
| 2026-02-28 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -1.07k | 559.35k | Sale to Issuer | 521.11 | 25.45k | -4.05% |
| 2026-02-28 | Mr. Stephen Williamsonインサイダー | -921.79 | 480.36k | Sale to Issuer | 521.11 | 45.17k | -2.00% |
| 2026-02-28 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -815.85 | 425.15k | Sale to Issuer | 521.11 | 19.93k | -3.93% |
| 2026-02-28 | Mr. Frederick M. Loweryインサイダー | -896.97 | 467.42k | Sale to Issuer | 521.11 | 13.46k | -6.25% |
| 2026-02-09 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400.00 | 216.48k | Automatic Disposition | 541.20 | 20.75k | -1.89% |
| 2025-12-10 | Mr. Scott M. SperlingIndependent Lead Director | -4.39k | 0.00 | Other Disposition | - | 68.42k | -6.02% |
| 2025-12-04 | Mr. Michel Lagardeインサイダー | 18.64k | 1.96M | Derivative Exercise and Retained Stock | 105.17 | 84.12k | 28.46% |
| 2025-12-04 | Mr. Michel Lagardeインサイダー | -22.05k | 9.50M | Derivative Exercise and Sale | 132.66 - 563.56 | 84.12k | - |
| 2025-12-02 | Mr. Michel Lagardeインサイダー | 42.00k | 4.42M | Derivative Exercise and Retained Stock | 105.17 | 65.48k | 178.88% |
| 2025-12-02 | Mr. Michel Lagardeインサイダー | -62.00k | 29.61M | Derivative Exercise and Sale | 105.17 - 584.11 | 65.48k | - |
| 2025-12-02 | Mr. Thomas Bailey ShropshireSenior VP and General Counsel | -337.48 | 195.86k | Sale to Issuer | 580.37 | 5.08k | -6.23% |
| 2025-12-01 | Mr. Frederick M. Loweryインサイダー | -13.83k | 4.64M | Derivative Exercise and Sale | 253.99 - 597.68 | 12.19k | - |
| 2025-11-25 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -10.73k | 3.62M | Derivative Exercise and Sale | 253.99 - 600.00 | 15.57k | - |
| 2025-11-14 | Mr. Stephen Williamsonインサイダー | -433.00 | 0.00 | Other Disposition | - | 44.56k | -0.96% |
| 2025-11-12 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -1.06k | 622.14k | 売り | 588.27 | 11.35k | -8.53% |
| 2025-11-13 | Mr. Michel Lagardeインサイダー | -4.64k | 1.58M | Derivative Exercise and Sale | 253.99 - 594.42 | 23.48k | - |
| 2025-11-10 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -2.98k | 879.81k | Derivative Exercise and Sale | 253.99 - 580.00 | 21.15k | - |
| 2025-11-07 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -8.48k | 2.69M | Derivative Exercise and Sale | 253.99 - 571.67 | 12.40k | - |
| 2025-11-07 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -1.75k | 999.95k | 売り | 571.40 | 12.40k | -12.36% |
| 2025-10-24 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400.00 | 229.66k | Automatic Disposition | 574.15 | 21.15k | -1.86% |
| 2025-10-24 | Mr. Marc N. CasperChairman & CEO | -24.35k | 7.73M | Derivative Exercise and Sale | 253.99 - 575.02 | 128.85k | - |
| 2025-09-05 | Mr. Marc N. CasperChairman & CEO | -400.00 | 98.61k | Derivative Exercise and Sale | 253.99 - 501.01 | 128.85k | - |
| 2025-08-28 | Mr. Marc N. CasperChairman & CEO | -1.41k | 691.19k | Sale to Issuer | 489.74 | 128.85k | -1.08% |
| 2025-08-28 | Mr. Stephen Williamsonインサイダー | -783.27 | 383.60k | Sale to Issuer | 489.74 | 44.99k | -1.71% |
| 2025-08-28 | Mr. Michael D. ShaferExec. VP & President of Biopharma Services | -598.09 | 292.91k | Sale to Issuer | 489.74 | 15.57k | -3.70% |
| 2025-08-28 | Mr. Frederick M. Loweryインサイダー | -667.72 | 327.01k | Sale to Issuer | 489.74 | 12.19k | -5.20% |
| 2025-08-28 | Mr. Michel Lagardeインサイダー | -961.20 | 470.74k | Sale to Issuer | 489.74 | 23.48k | -3.93% |
| 2025-08-29 | Mr. Joseph R. HolmesVP & CAO | -385.00 | 91.88k | Derivative Exercise and Sale | 253.99 - 492.63 | 1.96k | - |
| 2025-08-28 | Mr. Joseph R. HolmesVP & CAO | -36.98 | 18.11k | Sale to Issuer | 489.74 | 1.96k | -1.85% |
| 2025-08-28 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -814.70 | 398.99k | Sale to Issuer | 489.74 | 21.55k | -3.64% |
| 2025-08-28 | Ms. Lisa P. BrittChief HR Officer & Senior VP | -328.78 | 161.02k | Sale to Issuer | 489.74 | 14.15k | -2.27% |
| 2025-08-22 | Mr. Marc N. CasperChairman & CEO | -10.00k | 2.47M | Derivative Exercise and Sale | 253.99 - 502.26 | 130.26k | - |
| 2025-08-19 | Mr. Marc N. CasperChairman & CEO | -496.00 | 122.07k | Derivative Exercise and Sale | 253.99 - 500.17 | 130.26k | - |
| 2025-08-06 | Mr. Marc N. CasperChairman & CEO | -18.00k | 3.58M | Derivative Exercise and Sale | 253.99 - 464.68 | 125.84k | - |
| 2025-07-25 | Mr. Gianluca PettitiPresident, COO & President of Products and Technologies | -400.00 | 191.99k | Automatic Disposition | 479.98 | 22.37k | -1.76% |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
